The B3A2 junction type of the BCR-ABL oncogene is a favorable prognostic factor for a complete response to interferon treatment in patients with chronic myeloid leukemia (CML)

Posthuma, EFM; de Paus, R; Kluin-Nelemans, H; Beverloo, B; Mensink, E; Meijerink, JPP; Smit, B; Hagemeijer-Hausman, Anne; Wiliemze, R; Falkenburg, JHF

Blood

The B3A2 junction type of the BCR-ABL oncogene is a favorable prognostic factor for a complete response to interferon treatment in patients with chronic myeloid leukemia (CML)

Author:

Posthuma, EFM

de Paus, R ; Kluin-Nelemans, H ; Beverloo, B ; Mensink, E ; Meijerink, JPP ; Smit, B ; Hagemeijer-Hausman, Anne ; Wiliemze, R ; Falkenburg, JHF

Keywords:

Science & Technology, Life Sciences & Biomedicine, Hematology, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine, Immunology, 3101 Biochemistry and cell biology, 3201 Cardiovascular medicine and haematology, 3213 Paediatrics

Blood The B3A2 junction type of the BCR-ABL oncogene is a favorable prognostic factor for a complete response to interferon treatment in patients with chronic myeloid leukemia (CML)

Author:

Keywords:

Blood

The B3A2 junction type of the BCR-ABL oncogene is a favorable prognostic factor for a complete response to interferon treatment in patients with chronic myeloid leukemia (CML)